CYSLTR1 and bronchiectasis: To our knowledge, no studies have been conducted so far to evaluate the role of the leukotriene cysLT/cysLTr1 axis in the management of clinical and inflammatory outcomes within a population of patients with severe asthma on biological therapy and non-CF (non-cystic fibrosis) and non-ABPA (non-allergic bronchopulmonary aspergillosis) bronchiectasis.